SV News
14 March 2024Portfolio NewsCumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer's Dementia
11 March 2024Portfolio NewsNitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
11 March 2024Portfolio NewsRibometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting- 8 March 2024SV NewsOn International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies
- 23 February 2024SV NewsHow Precision Neuroscience and Drug Synergies Could Revolutionize Neurology
- 22 February 2024SV NewsPrecision Neuroscience: A New Frontier in Dementia Research and Beyond
13 February 2024Portfolio NewsTransposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyo
13 February 2024Portfolio NewsSudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
24 January 2024Portfolio NewsAmphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders- 12 January 2024SV NewsThe deal flow just gets better and better”: how Europe's startups are pushing progress for neurodegenerative diseases
- 3 January 2024Portfolio NewsQurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing
28 November 2023Portfolio NewsHarness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
